https://www.selleckchem.com/pr....oducts/bay-61-3606.h
To assess the outcome of nonagenarians patients receiving transcatheter aortic valve replacement (TAVR). We aimed to stratify the overall population from an Italian, multicenter, observational project including a total of 3792 consecutive patients who underwent TAVR with CoreValve and Evolut R/PRO devices between April 2009 and October 2018, into four groups according to their age class (≥90 vs. 80-89 years vs. 70-79 vs. 70 years) and to compare outcomes up to 4 years after TAVR. At 4 years, survival estimates showed no differen
Like
Comment
Share
